NI200800020A - 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización. - Google Patents

7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización.

Info

Publication number
NI200800020A
NI200800020A NI200800020A NI200800020A NI200800020A NI 200800020 A NI200800020 A NI 200800020A NI 200800020 A NI200800020 A NI 200800020A NI 200800020 A NI200800020 A NI 200800020A NI 200800020 A NI200800020 A NI 200800020A
Authority
NI
Nicaragua
Prior art keywords
indazoles
aza
compositions
contain
substituted
Prior art date
Application number
NI200800020A
Other languages
English (en)
Inventor
Bjergarde Kirsten
Nair Anil
Patek Marcel
Dodson Mark
Ackerman-Berrier Martha
Smrcina Martin
Leroy Vicent
Bacque Eric
Tabart Michel
Ronan Baptiste
Viviani Fabrice
Souaille Catherine
Original Assignee
Aventis Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma filed Critical Aventis Pharma
Publication of NI200800020A publication Critical patent/NI200800020A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a nuevos 7-aza-indazoles de fórmula (I) específicos que presentan una actividad moduladora de la actividad de proteínas, en particular de quinasas, a las composiciones que los contienen y su utilización como medicamento, particularmente como agentes anticancerígenos.
NI200800020A 2005-08-04 2008-01-18 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización. NI200800020A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0508316A FR2889526B1 (fr) 2005-08-04 2005-08-04 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation

Publications (1)

Publication Number Publication Date
NI200800020A true NI200800020A (es) 2011-01-10

Family

ID=36177926

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200800020A NI200800020A (es) 2005-08-04 2008-01-18 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización.

Country Status (30)

Country Link
US (1) US8058290B2 (es)
EP (1) EP1912988B1 (es)
JP (1) JP5128475B2 (es)
KR (1) KR101263970B1 (es)
CN (2) CN102093353B (es)
AR (1) AR057719A1 (es)
AU (1) AU2006277855B2 (es)
BR (1) BRPI0614304A2 (es)
CA (1) CA2617293C (es)
CR (1) CR9678A (es)
DO (1) DOP2006000179A (es)
EA (1) EA019302B1 (es)
EC (1) ECSP088152A (es)
FR (1) FR2889526B1 (es)
HK (1) HK1125928A1 (es)
HN (1) HN2008000188A (es)
IL (1) IL188792A0 (es)
MA (1) MA29652B1 (es)
MX (1) MX2008001614A (es)
MY (1) MY147488A (es)
NI (1) NI200800020A (es)
NO (1) NO20081013L (es)
NZ (1) NZ565396A (es)
PE (1) PE20070240A1 (es)
TN (1) TNSN08024A1 (es)
TW (1) TWI378930B (es)
UA (1) UA94417C2 (es)
UY (1) UY29727A1 (es)
WO (1) WO2007017577A1 (es)
ZA (1) ZA200800965B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20061119A1 (es) * 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
CA2645137A1 (en) 2006-03-07 2007-09-13 James F. Blake Heterobicyclic pyrazole compounds and methods of use
US8931114B2 (en) 2008-09-22 2015-01-13 The United States Of America, As Represented By The Secretary Of The Navy Elastomeric composites with tether-containing, conducting polymers for nanoscale diffusion control
US8120893B2 (en) * 2008-09-22 2012-02-21 The United States Of America As Represented By The Secretary Of The Navy Tether-containing conducting polymers
EP2426135A4 (en) * 2009-04-27 2013-02-20 Shionogi & Co UREA DERIVATIVE WITH PI3K-INHIBITING EFFECT
EP2464647B1 (en) 2009-08-11 2016-09-21 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
MX2012002317A (es) 2009-08-24 2012-06-25 Ascepion Pharmaceuticals Inc Compuestos de urea que contienen heteroarilo 5,6-biciclicos como inhibidores de cinasa.
EP2491033A4 (en) * 2009-10-20 2013-03-13 Eiger Biopharmaceuticals Inc AZAINDAZOLES FOR THE TREATMENT OF FLAVIVIRIDAE VIRUS INFECTION
FR2954943B1 (fr) * 2010-01-07 2013-03-01 Sanofi Aventis Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique
EP2566479B1 (en) * 2010-05-07 2014-12-24 GlaxoSmithKline LLC Azaindazoles
US20130102477A1 (en) 2010-06-23 2013-04-25 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
ES2570380T3 (es) 2010-09-10 2016-05-18 Epizyme Inc Método para determinar la aptitud de inhibidores de EZH2 humano en tratamiento
EP3323820B1 (en) * 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
EP2755962B1 (en) 2011-09-13 2017-03-01 Glaxosmithkline LLC Azaindazoles
EP2760862B1 (en) * 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
FR2984325A1 (fr) * 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
US10138235B2 (en) 2011-12-14 2018-11-27 Sanofi Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof
HUE060881T2 (hu) 2012-04-13 2023-04-28 Epizyme Inc Sóforma az EZH2 gátláshoz
EP2847191B1 (en) 2012-05-09 2016-06-15 Sanofi Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
RU2662436C2 (ru) 2012-10-15 2018-07-26 Эпизайм, Инк. Содержащие заместители бензольные соединения
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
TWI629275B (zh) * 2013-03-13 2018-07-11 賽諾菲公司 Ｎ－（４－（氮雜吲唑－６－基）－苯基）－磺醯胺及其作為醫藥之用途
SG10201901977XA (en) 2013-10-16 2019-04-29 Epizyme Inc Hydrochloride salt form for ezh2 inhibition
AP2016009605A0 (en) 2014-06-17 2016-12-31 Pfizer Substituted dihydroisoquinolinone compounds
WO2017053604A1 (en) * 2015-09-23 2017-03-30 The Regents Of The University Of California Potent antiviral pyrazolopyridine compounds
CN107619388A (zh) * 2016-07-13 2018-01-23 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
CN107840842A (zh) 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
CR20190145A (es) 2016-09-23 2019-06-03 Novartis Ag Compuestos de indazol para usar en lesiones de tendones y/o ligamentos
JP7233715B2 (ja) * 2016-12-07 2023-03-07 オリモス セラピューティクス カンパニー， リミテッド Ｓｇｋ活性を調節するための化合物及び医薬組成物、並びにその方法
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
CN111138426B (zh) * 2018-11-02 2023-03-10 安徽中科拓苒药物科学研究有限公司 吲唑类激酶抑制剂及其用途
CN109456280B (zh) * 2018-12-24 2020-11-10 锦州医科大学 含有脲结构的4-苯基噻唑-2-胺类衍生物及其制备方法与应用
WO2020178316A1 (en) * 2019-03-05 2020-09-10 Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.P.A. 5- or 7-azaindazoles as beta-lactamase inhibitors
WO2021007477A1 (en) 2019-07-11 2021-01-14 E-Scape Bio, Inc. Indazoles and azaindazoles as lrrk2 inhibitors
AR126251A1 (es) 2021-06-28 2023-10-04 Blueprint Medicines Corp Inhibidores de cdk2

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1302287A (es) * 1970-07-21 1973-01-04
DE2538950A1 (de) * 1975-09-02 1977-03-03 Basf Ag Verfahren zur herstellung von 2,6- dichlor-nicotinsaeuren
DE2701610A1 (de) * 1977-01-17 1978-07-20 Basf Ag Farbstoffzubereitungen fuer cellulose und cellulosehaltiges textilmaterial und neue farbstoffe
DD154538A1 (de) * 1979-07-30 1982-03-31 Eberhard Schroetter Verfahren zur herstellung substituierter 2,4-und 2,6-dihalogen-pyridine
JPH04117362A (ja) * 1990-09-07 1992-04-17 Idemitsu Kosan Co Ltd ピリジン誘導体およびその塩ならびに該物質を有効成分とする殺虫・殺ダニ剤
DE60037455T2 (de) * 1999-09-17 2008-11-27 Abbott Gmbh & Co. Kg Kinaseinhibitoren als arzneimittel
US7541354B2 (en) 2000-08-10 2009-06-02 Pfizer Italia S.R.L. Bicyclo-pyrazoles
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
US6977262B2 (en) * 2001-02-02 2005-12-20 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds and pharmaceutical use thereof
FR2827603B1 (fr) * 2001-07-18 2003-10-17 Oreal Composes derives de diaminopyrazole substitues par un radical heteroaromatique et leur utilisation en teinture d'oxydation des fibres keratiniques
WO2003027101A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl pyrroles and 3-pyridyl pyrazoles as c17,20 lyase inhibitors
GB0128287D0 (en) 2001-11-26 2002-01-16 Smithkline Beecham Plc Novel method and compounds
WO2003068773A1 (en) * 2002-02-12 2003-08-21 Glaxo Group Limited Pyrazolopyridine derivatives
WO2004009596A2 (en) 2002-07-23 2004-01-29 Smithkline Beecham Corporation Pyrazolopyrimidines as kinase inhibitors
BR0313396A (pt) 2002-08-12 2005-06-28 Sugen Inc 3-pirrolil-piridopirazóis e 3-pirrolil-indazóis, como inibidores de quinase
DE602004029145D1 (de) 2003-02-27 2010-10-28 Palau Pharma Sa Pyrazolopyridin-derivate
EP1620095A4 (en) * 2003-04-24 2009-04-01 Merck & Co Inc INHIBITORS OF AKT ACTIVITY
AU2004259012C1 (en) 2003-07-23 2012-08-02 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
WO2005027095A1 (ja) 2003-09-16 2005-03-24 Matsushita Electric Industrial Co., Ltd. 符号化装置および復号化装置
KR100703068B1 (ko) * 2003-12-30 2007-04-05 에스케이케미칼주식회사 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
GB0402137D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
US20060074102A1 (en) 2004-05-14 2006-04-06 Kevin Cusack Kinase inhibitors as therapeutic agents
FR2871158A1 (fr) * 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2006076442A2 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives
PE20061119A1 (es) 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
ES2543607T3 (es) 2005-03-10 2015-08-20 Gilead Connecticut, Inc. Ciertas amidas sustituidas, método de obtención, y método de su uso
EP1876178B1 (en) 2005-04-28 2015-05-27 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and use thereof as medicine
CA2627089A1 (en) 2005-11-09 2007-05-18 Memory Pharmaceuticals Corporation 1 h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof

Also Published As

Publication number Publication date
US20080182844A1 (en) 2008-07-31
UY29727A1 (es) 2007-02-28
TWI378930B (en) 2012-12-11
KR101263970B1 (ko) 2013-05-13
IL188792A0 (en) 2008-08-07
ZA200800965B (en) 2009-11-25
CR9678A (es) 2008-09-22
WO2007017577A1 (fr) 2007-02-15
CA2617293C (fr) 2015-09-22
MX2008001614A (es) 2008-04-04
AU2006277855A1 (en) 2007-02-15
CN102093353A (zh) 2011-06-15
PE20070240A1 (es) 2007-04-12
US8058290B2 (en) 2011-11-15
NZ565396A (en) 2011-03-31
HK1125928A1 (en) 2009-08-21
CN101304998A (zh) 2008-11-12
ECSP088152A (es) 2008-02-20
TW200745103A (en) 2007-12-16
JP2009503037A (ja) 2009-01-29
MA29652B1 (fr) 2008-07-01
TNSN08024A1 (en) 2009-07-14
CA2617293A1 (fr) 2007-02-15
CN101304998B (zh) 2012-09-05
DOP2006000179A (es) 2007-03-31
CN102093353B (zh) 2013-06-12
FR2889526B1 (fr) 2012-02-17
EP1912988B1 (fr) 2014-04-16
EA019302B1 (ru) 2014-02-28
UA94417C2 (ru) 2011-05-10
AR057719A1 (es) 2007-12-12
AU2006277855B2 (en) 2012-08-23
MY147488A (en) 2012-12-14
BRPI0614304A2 (pt) 2011-03-22
JP5128475B2 (ja) 2013-01-23
FR2889526A1 (fr) 2007-02-09
KR20080031939A (ko) 2008-04-11
EA200800514A1 (ru) 2008-06-30
EP1912988A1 (fr) 2008-04-23
NO20081013L (no) 2008-04-14
HN2008000188A (es) 2010-11-09

Similar Documents

Publication Publication Date Title
NI200800020A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización.
ECSP088252A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
CR9463A (es) Pirrolinas sustituidas, composiciones que las contienen, proceso de fabricacion y utilizacion
UY29341A1 (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricación
UY29248A1 (es) Indoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
SV2011003855A (es) Heteroarilos sustituidos
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
ECSP10010735A (es) Compuestos químicos 251
UY30195A1 (es) Derivados de fenetanolamina, procedimiento de preparacion, composiciones que los contienen y aplicaciones
ECSP067120A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
UY29486A1 (es) Compuestos utiles en terapia
UY29361A1 (es) Pirroles e imidazoles sustituídos, composiciones que los contienen, procedimiento de fabricación y utilización
CR20110381A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
HN2011002578A (es) Nuevos derivados de compuestos de [3,2-c]pirazol esteroidal con actividad clucocorticoide.
NI200900078A (es) Pirazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización.
DOP2006000015A (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricación
DOP2006000028A (es) Pirroles sustituidos, composiciones que los contienen, proceso de fabricación y utilización
CR9115A (es) Indoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
CR10390A (es) Derivados de 2-alcoxi-3,4,5-trihidroxi-alquilamida, su preparacion, composiciones que las contienen y utilizacion
CR10382A (es) 2-alcoxi-3,4,5-trihidroxi-alquilamida-benzazepinas, su preparacion, composiciones que las contienen y utilizacion
NI201200103A (es) NUEVOS DERIVADOS ( HETEROCICLO - TETRAHIDRO - PIRIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y ( HETEROCICLO - DIHIDRO - PIRROLIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y SU UTILIZACIÓN COMO INHIBIDORES DE p75
CR10428A (es) 2-alcoxi-3,4,5-trihidroxi-alquilamida-benzotiazepinas, su preparacion, composiciones que las contienen y utilizacion
DOP2005000246A (es) Indoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
GT200700016A (es) 7-aza-indazoles sustituidos; composiciones que les contienen; procedimiento de fabricación y utilización.
UY29501A1 (es) Pirrolopiridinas sustituidas, composiciones que las contienen, proceso de fabricación y utilización